Share this Post!

In compliance with Republic Act No. 10354, also known as “The Responsible Parenthood and Reproductive Health (RH) Act of 2012” and its IRR, the Food and Drug Administration (FDA) hereby invites all interested parties to submit position papers and any corresponding evidences on submitted non-abortifacient property evidence of the applicant below within ten (10) working days from the posting of this Advisory:  

 

Generic Name  Dosage Strength and Form  Brand Name  Applicant 
  1. Levonorgestrel 
75 mg Subdermal Implant   Levoplant  DKT Health, Inc. 

 

Position papers, documents and scientific evidence can be submitted via email to the Food and Drug Action Center (FDAC) fdac.letters.cdrr@fda.gov.ph on Mondays to Fridays, 8:00 AM to 5:00 PM. 

Attachments